The Voltaren Wärmepflaster. Targeted warmth for stressed backs

Voltaren Wärmepflaster comes out of the foil pack with a faint medicinal smell and a soft, almost velvety surface that clings to the lower back. After a few minutes the patch begins to warm, a steady, gentle heat instead of a sudden blast.

How the heat patch works

Voltaren Wärmepflaster is a self-heating patch from Haleon targeting localized back and muscle pain without any added drug ingredient. The patch uses an iron-powder based heat cell that reacts with oxygen and produces consistent warmth once the pouch is opened.

According to a Haleon consumer health specialist, Dr. Anna Keller, the goal is simple: keep the temperature in a therapeutic range while the user moves, sits at a desk, or lies on the sofa. She explains that the patch is designed to maintain heat for up to eight hours of wear.

Usage, sizing and comfort

The Voltaren Wärmepflaster for the back is a rectangular pad, typically sized to cover the central lumbar area or a broader muscle group, depending on the variant. Users peel away the protective film and apply the adhesive side directly on dry, intact skin over the painful area.

Haleon recommends leaving the patch in place for up to eight hours on adults, with no more than one patch used on the same area in a 24-hour period. Dr. Keller emphasizes that patients with very sensitive skin should check after a short time whether redness or irritation develops.

Position in Haleon’s Voltaren line

Within Haleon’s Voltaren brand, the Wärmepflaster sits alongside gels containing diclofenac and other topical formats that deliver anti-inflammatory medicine through the skin. Unlike Voltaren Schmerzgel, this heat patch relies purely on physical warmth and contains no diclofenac or ibuprofen.

That positioning allows Haleon to address consumers who prefer to avoid additional pain medicines or who already use oral analgesics and want a non-pharmacological add-on. The company presents the patch as a complementary option in its broader musculoskeletal pain toolkit.

Regulatory and safety aspects

Because Voltaren Wärmepflaster is a drug-free device, in many European markets it is classified as a medical device rather than a medicinal product. This means Haleon must meet device safety and performance requirements, covering adhesive quality, skin compatibility and temperature control.

The company’s product information stresses that the patch should not be used while sleeping, on bruised or inflamed skin, or by individuals who cannot sense heat properly, such as some people with neuropathy. Children, pregnant women and people with circulatory problems are advised to consult a doctor or pharmacist before use.

Distribution and availability

Voltaren Wärmepflaster is sold primarily through pharmacies and drugstores in markets such as Germany, Austria and Switzerland, often in packs of two or more patches. Online pharmacy listings show it positioned in the back-pain segment with clear instructions on single-use application and disposal.

Prices vary by pack size and retailer, but in Germany a multi-patch pack typically lands in the mid single-digit to low double-digit euro range. That puts it between one-off disposable heat wraps and higher-priced reusable electric pads.

Competitive landscape in heat therapy

Haleon faces competition from generic heat patches, private-label drugstore brands and specialist heat-wrap manufacturers. Many of these rivals also use iron-based heat cell technology with similar eight-hour claims and adhesive backing. Differentiation often comes down to brand, fit and skin feel.

Voltaren brings strong brand recognition from its gels and oral products, which may help win shelf space and consumer trust. However, Haleon still has to compete on practical details such as whether the patch holds during movement, how easily it peels off, and how discreetly it sits under clothing.

Haleon stock context

For Haleon, OTC pain management remains a core revenue pillar, and expanding physical-therapy options like Voltaren Wärmepflaster fits the broader strategy set out by CEO Brian McNamara to grow in everyday health segments. On the London Stock Exchange, Haleon PLC stock trades under ISIN GB00BMX86B70.